samedan logo
 
 
 
spacer
home > ebr > autumn 2020 > the numerous challenges of a rapidly developing sector
PUBLICATIONS
European Biopharmaceutical Review

The Numerous Challenges of a Rapidly Developing Sector

Farmers have manipulated agriculture and livestock for thousands of years. It’s no surprise, then, that discovery and development are the primary goal of each of the four biotechnology markets, including:

• Bio-health: Bio-health companies are hyper-focused on the R&D portion of the medical sector. These companies take significant risks to design new drugs quicker and more effectively. Bio-health thrives ‘behind the scenes’, starting with foundational research to product launch instead of marketing or sales
• Agri-biotech: Ground-breaking agricultural advances have always played a vital role in agri-biotech. For example, scientists successfully cloned the first mammal in 1996 – a sheep named Dolly. Aside from animal cloning however, agri-biotech pursues crop improvement by crop cloning, modifying genes, and more. Many farmers thrive on transgenic and bioengineered crops, too
• Bio-energy: The biotech industry solves environmental problems by studying natural environments. The bio-energy market studies microorganisms and works to create a more sustainable and preserved world with less pollution
• Bioindustrial: More than for medicine, food, or energy, biotech focuses on non-food uses of crops and other products. The bioindustrial market can transform unpalatable raw materials into edible food. Additionally, the biotech industry’s advances have extended the shelf-life of many foods based on innovative packaging and product storage

Navigating the Legal Climate of Biotech

Plenty of legal issues surrounding the biotech industry are cause for concern with those involved in the space. Furthermore, each legal layer, or apprehension, indirectly contributes to the complexity of this market. There are vulnerabilities abound, but players tend to weigh their options differently than in any other industry.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Carl Niedbala is the Co-Founder and Chief Operating Officer of Founder Shield, a boutique insurance brokerage specialised in serving emerging industries and the life sciences sector. Founder Shield works with forward-thinking insurers, and focuses on using technology to deliver top tier service and results. Carl’s experience began in high school when he developed and submitted United States Patent Application 20050277574, published 15 December 2005. Carl studied finance and marketing at Villanova University, US, before attending the Temple Beasley School of Law, US. After working for several venture backed start-ups and venture funds, including Dreamit Ventures and biotech-focused Originate Ventures, Carl co-founded Founder Shield.
spacer
Carl Niedbala
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETOT (pralsetinib)

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
More info >>

White Papers

Speciality Logistics Outlook 2015

World Courier

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement